Image Guided Radiation Therapy Market

Market Definition

Image-guided radiation therapy (IGRT) is an integrated approach used in cancer treatment. This approach combines advanced imaging technologies with radiation delivery systems to improve targeting precision. IGRT allows clinicians to track tumor position and adjust patient alignment in real time, which helps reduce radiation exposure to healthy tissues.

The market scope covers oncology centers, hospitals, and treatment facilities specializing in cancer treatment. Healthcare providers use this technique for treating tumors in the brain, lungs, prostate, and other areas where high accuracy is critical.

Image Guided Radiation Therapy Market Overview

The global image guided radiation therapy market size was valued at USD 2,210.0 million in 2024 and is projected to grow from USD 2,368.3 million in 2025 to USD 4,085.3 million by 2032, exhibiting a CAGR of 8.10% during the forecast period.

The growth of the market is driven by advancements in imaging-integrated radiotherapy, which offer precise tumor targeting and reduce damage to surrounding tissues. Additionally, AI-enhanced MRI-guided radiotherapy improves treatment accuracy and workflow efficiency, while rising cancer incidence increases the demand for advanced, minimally invasive radiotherapy solutions.

Key Highlights

1. The image guided radiation therapy industry size was recorded at USD 2,210.0 million in 2024.
2. The market is projected to grow at a CAGR of 8.10% from 2025 to 2032.
3. North America held a market share of 35.55% in 2024, with a valuation of USD 785.7 million.
4. The Radiation Delivery Systems segment garnered USD 1,019.7 million in revenue in 2024.
5. The Volumetric Modulated Arc Therapy segment is expected to reach USD 1,484.4 million by 2032.
6. The Breast Cancer segment secured the largest revenue share of 25.42% in 2024.
7. The Academic & Research Institutions segment is poised to grow at a robust CAGR of 10.24% through the forecast period.
8. Asia Pacific is anticipated to grow at a CAGR of 10.18% during the forecast period.

Major companies operating in the global image guided radiation therapy market are Siemens, Elekta, Accuray Incorporated, ViewRay Systems, Inc., Hitachi High-Tech Corporation, CANON MEDICAL SYSTEMS CORPORATION, Brainlab SE, Panacea Medical Technologies Pvt. Ltd., Mevion Medical Systems, General Electric Company, Koninklijke Philips N.V., TOSHIBA CORPORATION, Vision RT Ltd., C-RAD, and RaySearch Laboratories AB.

The increasing global incidence of cancer, coupled with the healthcare industry’s move toward personalized medicine, is fueling the adoption of image guided radiation therapy. The World Health Organization reported an estimated 20 million new cancer cases globally in 2022 and projected a 77% increase in annual cancer cases by 2050.

Advances in genomics, molecular profiling, and biomarker identification enable clinicians to design more precise and patient-specific treatment plans. IGRT’s ability to accurately target tumors while minimizing exposure to surrounding healthy tissue aligns with these precision oncology goals, improving therapeutic outcomes and reducing side effects.

Market Driver

Advancements in Imaging-Integrated Radiotherapy

The integration of advanced imaging modalities such as computed tomography (CT), four-dimensional radiation therapy (4D-RT), magnetic resonance imaging (MRI)-guided radiotherapy, and cone-beam computed tomography (CBCT) into linear accelerators (LINACs) is significantly improving treatment precision. 

These technologies enable the real-time visualization of tumor position, shape, and motion, allowing clinicians to adapt radiation delivery dynamically during each session. This capability reduces targeting errors, minimizes radiation exposure to healthy tissue, and supports more effective and personalized cancer treatment strategies.

• In July 2024, Kauno klinikos installed one of the first MRI-LINAC systems in the Baltic States,which is the only such system in Lithuania, combining MRI imaging and radiation delivery for adaptive radiotherapy. This hybrid system allows the precise and real-time visualization of tumors and adaptive dosing to minimize radiation exposure to healthy tissues.

Market Challenge

High Capital Investment and Treatment Costs

A significant challenge impeding the progress of the image guided radiation therapy market is managing the substantial capital required for equipment procurement and facility setup. IGRT systems involve advanced imaging technologies integrated with radiation delivery platforms, which significantly increase purchase and installation expenses. 

Additionally, ongoing maintenance, calibration, and the need for specialized personnel contribute to high operational costs, making adoption difficult for healthcare providers in resource-limited settings.

To address this challenge, market players are developing cost-efficient system configurations, offering flexible financing models, and providing training programs to optimize operational efficiency. These strategies are helping broaden access to the IGRT technology while improving long-term cost management for healthcare facilities.

Market Trend

AI-Enhanced MRI-Guided Radiotherapy

The image guided radiation therapy market is advancing through the integration of artificial intelligence with MRI-guided linear accelerators (MRI-LINACs). These systems combine high-resolution, real-time imaging with AI algorithms to track tumor motion, including breathing-induced shifts, throughout treatment sessions. 

This capability improves targeting precision, enabling adaptive dose delivery that spares surrounding healthy tissues. The approach is particularly valuable for tumors in anatomically dynamic regions, enhancing treatment safety and efficacy while supporting the wider adoption of adaptive radiotherapy protocols.

• In May 2024, Elekta officially launched its Elekta Evo CT-Linac at the ESTRO 2024 conference in Glasgow. This CT-Linac features high-definition AI-enhanced imaging and supports online and offline adaptive radiation therapy, along with standard IGRT capabilities.

Image Guided Radiation Therapy Market Report Snapshot

Market Segmentation

• By Product Type (Radiation Delivery Systems, Imaging Systems, Positioning & Motion Management Devices, Software Solutions, and Services): The radiation delivery systems segment earned USD 1,019.7 million in 2024 due to its central role in treatment, high adoption across hospitals and cancer centers, and continuous technological advancements.
• By Procedure (3D Conformal Radiation Therapy, Stereotactic Body Radiation Therapy, Particle Therapy, Volumetric Modulated Arc Therapy, Proton Beam Therapy, and Others): The volumetric modulated arc therapy segment held 36.63% of the market in 2024, due to its ability to deliver highly precise, conformal doses in shorter treatment durations.
• By Application (Breast Cancer, Lung Cancer, Prostate Cancer, Gastrointestinal Cancers, Gynecologic Cancers, and Others): The breast cancer segment is projected to reach USD 1,162.9 million by 2032, owing to its high prevalence, increasing early detection rates, and the clinical need for precise targeting to minimize radiation exposure to surrounding healthy tissues.
• By End User (Hospitals, Academic & Research Institutions, and Ambulatory Radiation Therapy Clinics): The academic & research institutions segment is poised for significant growth at a CAGR of 10.24% over the forecast period, attributed to its role in developing, testing, and implementing advanced technologies such as AI-enhanced MRI-guided radiotherapy and imaging-integrated treatment systems.

Image Guided Radiation Therapy Market Regional Analysis

Based on region, the market has been classified into North America, Europe, Asia Pacific, the Middle East & Africa, and South America.

North America image guided radiation therapy market share stood at 35.55% in 2024, with a valuation of USD 785.7 million. This dominance is attributed to the rapid integration of high-resolution imaging technologies, including MRI-guided linear accelerators and PET-CT, into radiation therapy workflows across hospitals and cancer centers in the region. 

These systems enable precise tumor targeting during treatment, improving clinical outcomes and reducing side effects. The widespread adoption of such hybrid platforms has significantly increased the incorporation of IGRT in treatment protocols.

• In June 2024, Siemens Healthineers launched the Biograph Trinion, a high-performance, energy-efficient PET/CT scanner that received FDA 510(k) clearance. Key features include fast, low-dose imaging, high spatial resolution, time-of-flight performance, and integrated PET/CT workflows, which can enhance the imaging backbone supporting IGRT protocols.

Asia Pacific image guided radiation therapy industry is poised to grow at a CAGR of 10.18% over the forecast period. This growth is driven by the rapid expansion of cancer treatment infrastructure in the region through large-scale public health initiatives and private hospital investments. 

New cancer centers are being designed and equipped with IGRT-ready systems from the outset, eliminating the delays and costs associated with upgrading older equipment. This approach allows Asia Pacific to adopt advanced platforms more quickly than mature markets, where retrofitting is often necessary.

• In September 2024, Fortis Memorial Research Institute in Gurugram unveiled the Elekta Unity MR-Linac, the first MRI-guided linear accelerator (MRI-LINAC) in North India, which combines a 1.5 T MRI scanner with a linear accelerator for real-time imaging during treatment. This technology enables clinicians to visualize tumor position and anatomy continually during therapy and adapt the treatment dynamically to enhance precision.

Additionally, the rising incidence of lung, gastrointestinal, and head & neck cancers is creating a strong clinical need for highly precise targeting and motion management. By reducing radiation exposure to healthy tissues, IGRT meets this need effectively, making it an increasingly preferred option across oncology practices in the region.

Regulatory Frameworks

• The U.S. Food and Drug Administration (FDA) regulates radiotherapy equipment and software as medical devices (510(k) or Premarket Approval routes), while the U.S. Nuclear Regulatory Commission (NRC) and state radiation control programs oversee radioactive materials and therapeutic X-ray operations. Hospitals must obtain device clearance and comply with state inspection and NRC requirements where applicable.
• In the European Union, medical devices, including IGRT hardware and software, must comply with the Medical Device Regulation (MDR 2017/745) and undergo conformity assessment. Radiation protection for patient exposures is mandated by the Euratom Basic Safety Standards (Council Directive 2013/59/Euratom), which member states transpose into national law covering justification, optimization, and clinical audit.
• In China, the National Medical Products Administration (NMPA) regulates the registration and technical review of radiotherapy devices, as complex systems require detailed technical dossiers and local testing. Provincial health and radiation safety authorities enforce facility licensing, shielding, and operational safety standards before beginning treatments.
• In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) enforces device review under the Pharmaceuticals and Medical Devices Act (PMD Act). High-risk radiotherapy systems and treatment-planning software require PMDA review and Ministry of Health, Labour and Welfare approval; post-market surveillance and human-factors evidence are commonly required for complex platforms.

Competitive Landscape

Market players in the image guided radiation therapy industry are increasing research and development, strategic partnerships, and technological advancements to maintain competitiveness. Companies are focusing on developing AI-enabled solutions, enhancing software integration, and improving imaging and treatment planning capabilities. 

Investments in advanced platforms, workflow automation, and collaboration with third-party technology providers are helping vendors offer more precise, efficient, and user-friendly radiation therapy systems. This is strengthening their position in the image-guided radiation therapy market.

• In May 2025, GE HealthCare announced the expansion of its radiation oncology portfolio at the ESTRO 2025 Congress , introducing several AI-enabled solutions, including MR Contour DL, an FDA-cleared deep-learning model for organs-at-risk (OAR) segmentation in MR images. The company also revealed its enhanced iRT (Intelligent Radiation Therapy) software, designed to integrate MR imaging workflows and third-party AI tools into streamlined treatment planning.

Key Companies in Image Guided Radiation Therapy Market:

• Siemens
• Elekta
• Accuray Incorporated
• ViewRay Systems, Inc.
• Hitachi High-Tech Corporation
• CANON MEDICAL SYSTEMS CORPORATION
• Brainlab SE
• Panacea Medical Technologies Pvt. Ltd.
• Mevion Medical Systems
• General Electric Company
• Koninklijke Philips N.V
• TOSHIBA CORPORATION
• Vision RT Ltd.
• C-RAD
• RaySearch Laboratories AB

Recent Developments (Government Approvals)

• In July 2025, Royal Philips received  FDA) 510(k) clearance for its updated UroNav system, designed for image-guided navigation in prostate cancer care. The latest version features an enhanced annotation workflow that assists clinicians during focal therapy procedures, enabling more precise and minimally invasive treatment delivery.
• In March 2025, SkinCure Oncology, a global leader in delivering Image-Guided Superficial Radiation Therapy for nonmelanoma skin cancer through its GentleCure Experience for dermatology patients, announced the submission of its GentleBeam technology to the FDA for 510(k) clearance.